These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 8032298)

  • 1. C3d levels in normal individuals of Chinese origin.
    Wan KC; Lewis WH
    Br J Biomed Sci; 1993 Mar; 50(1):8-12. PubMed ID: 8032298
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A longitudinal study of C3, C3d and factor Ba in burn patients in Hong Kong Chinese.
    Wan KC; Lewis WH; Leung PC; Chien P; Hung LK
    Burns; 1998 May; 24(3):241-4. PubMed ID: 9677027
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Urinary C3d is elevated in patients with active Lupus nephritis and a fall in its level after 3 months predicts response at 6 months on follow up.
    Ganguly S; Majumder S; Kumar S; Gupta R; Muhammed H; Shobha V; Aggarwal A; Misra R
    Lupus; 2020 Nov; 29(13):1800-1806. PubMed ID: 32807020
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of renal failure on complement C3d levels.
    Krediet RT; Asghar SS; Koomen GC; Venneker GT; Struijk DG; Arisz L
    Nephron; 1991; 59(1):41-5. PubMed ID: 1944746
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum C3d levels in tropical pulmonary eosinophilia.
    Ray D; Subramanyam S; Krishna SH; Ramanathan VD
    Indian J Med Res; 2010 Apr; 131():555-8. PubMed ID: 20424307
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Local and systemic activation of the whole complement cascade in human leukocytoclastic cutaneous vasculitis; C3d,g and terminal complement complex as sensitive markers.
    Dauchel H; Joly P; Delpech A; Thomine E; Sauger F; Le Loet X; Lauret P; Tron F; Fontaine M; Ripoche J
    Clin Exp Immunol; 1993 May; 92(2):274-83. PubMed ID: 8485913
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Plasma complement 3d levels in the early phase after pancreas transplantation.
    Suermann A; Vonend O; Schenker P; Viebahn R; Rump LC; Weiner SM
    Ann Transplant; 2009; 14(3):29-35. PubMed ID: 19644157
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Plasma C3d/C3 quotient as a parameter for in vivo complement activation.
    Nürnberger W; Bhakdi S
    J Immunol Methods; 1984 Nov; 74(1):87-91. PubMed ID: 6334115
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Usefulness of complement activation products in Chinese patients with systemic lupus erythematosus.
    Li J; An L; Zhang Z
    Clin Exp Rheumatol; 2014; 32(1):48-53. PubMed ID: 23981509
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A new method for the estimation of C3d. Affinity clearance of C-determinant-bearing C3 molecules and fragments followed by estimation of C3d by ELISA.
    Asghar SS; Schraag B; Backhaus AH; Zorn I; Venneker GT; Hannema AJ
    J Immunol Methods; 1989 Jun; 120(2):207-14. PubMed ID: 2472454
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Quantification of the C3d split products of human complement by a sensitive enzyme-linked immunosorbent assay.
    Mollnes TE
    Scand J Immunol; 1985 Jun; 21(6):607-13. PubMed ID: 3895396
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Urinary excretion of complement C3d in patients with renal diseases.
    Branten AJ; Kock-Jansen M; Klasen IS; Wetzels JF
    Eur J Clin Invest; 2003 Jun; 33(6):449-56. PubMed ID: 12795640
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Complement fragment C3d is colocalized within the lipid rafts of T cells and promotes cytokine production.
    Borschukova O; Paz Z; Ghiran IC; Liu CC; Kao AH; Manzi S; Ahearn JM; Tsokos GC
    Lupus; 2012 Oct; 21(12):1294-304. PubMed ID: 22851413
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relationship between Mean Fluorescence Intensity and C1q/C3d-fixing capacities of anti-HLA antibodies.
    Claisse G; Absi L; Cognasse F; Alamartine E; Mariat C; Maillard N
    Hum Immunol; 2017 Apr; 78(4):336-341. PubMed ID: 28189573
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Complement degradation product C3d in urine: marker of lupus nephritis.
    Negi VS; Aggarwal A; Dayal R; Naik S; Misra R
    J Rheumatol; 2000 Feb; 27(2):380-3. PubMed ID: 10685801
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multimeric interactions between complement factor H and its C3d ligand provide new insight on complement regulation.
    Okemefuna AI; Li K; Nan R; Ormsby RJ; Sadlon T; Gordon DL; Perkins SJ
    J Mol Biol; 2009 Aug; 391(1):119-35. PubMed ID: 19505474
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Structural requirements for C3d,g/Epstein-Barr virus receptor (CR2/CD21) ligand binding, internalization, and viral infection.
    Carel JC; Myones BL; Frazier B; Holers VM
    J Biol Chem; 1990 Jul; 265(21):12293-9. PubMed ID: 1695627
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A novel antihuman C3d monoclonal antibody with specificity to the C3d complement split product.
    Rasmussen KJ; Skjoedt MO; Vitved L; Skjoedt K; Palarasah Y
    J Immunol Methods; 2017 May; 444():51-55. PubMed ID: 28174050
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Quantitation of red blood cell-bound C3d in normal subjects and random hospitalized patients.
    Chaplin H; Nasongkla M; Monroe MC
    Br J Haematol; 1981 May; 48(1):69-78. PubMed ID: 6972779
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Electrostatic Steering Accelerates C3d:CR2 Association.
    Mohan RR; Huber GA; Morikis D
    J Phys Chem B; 2016 Aug; 120(33):8416-23. PubMed ID: 27092816
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.